hVIVO PLC reported annual revenue of £46.7 million, which met market expectations, prompting City brokers to evaluate whether the clinical research organisation has begun to reverse its fortunes after a
hVIVO plc (AIM: HVO) Trading Update
FY25 revenue in line and positive adjusted EBITDA Positioned to return to growth in 2026
hVIVO plc (AIM: HVO) Notice of Trading Update
Notice of Trading Update
hVIVO plc (AIM: HVO) Appointment of Richard Cotton as Non-Executive Director
hVIVO strengthens Board with appointment of Richard Cotton as Non-Executive Director Seasoned life sciences executive with extensive Board and financial expertise
hVIVO plc (AIM: HVO) plays key role in $9.2bn Cidara takeover by MSD
hVIVO plc has highlighted a major validation of its clinical capabilities after its client Cidara Therapeutics agreed to be acquired by pharmaceutical giant MSD in a deal worth approximately $9.2
hVIVO plc (AIM: HVO) secures £5m+ in new clinical trial contracts
hVIVO plc has announced that its German subsidiary, CRS, has landed more than £5 million in new contracts since September, driven in large part by two returning mid-sized German pharmaceutical
hMPV Interview with Guy Boivin & hVIVO’s Chief Scientific Officer
Join us for an insightful conversation on hMPV featuring our Chief Scientific Officer, Dr Andrew Catchpole and Guy Boivin, a professor from Laval University and one of the founding fathers
hVIVO plc: Diversification in Action as 2026 Growth Beckons
After a turbulent year for the clinical research sector, hVIVO plc (AIM: HVO) has found itself back in penny-stock territory. Its share price, which stood at 29.8 GBX in November
hVIVO plc: Diversification in Action as 2026 Growth Beckons
After a turbulent year for the clinical research sector, hVIVO plc (AIM: HVO) has found itself back in penny-stock territory. Its share price, which stood at 29.8 GBX in November
hVIVO plc (AIM: HVO) Positive data from novel human challenge models
Positive data from multiple novel human challenge models hVIVO presentations made at influential ESWI and World Vaccine Congress Europe conferences
hVIVO plc (AIM: HVO) Presentation at Jefferies Healthcare Conference
hVIVO to present at Jefferies Global Healthcare Conference
hVIVO plc – Unaudited Interim Results for Six Months Ended 30 June 2025
Interim results Trading in line with expectations for full year Returning to growth in 2026